Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis
Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
Purpose: To determine whether oral viscous budesonide (OVB) or fluticasone metered dose
inhaler (MDI) most effectively treats EoE by improving histologic findings and symptoms,
which medication provides a more durable treatment response, and whether biomarkers can
predict treatment response.
Participants: A total of up to 200 16-80 year old patients with a new diagnosis of
eosinophilic esophagitis (EoE) who are referred for upper endoscopy will be consented with a
target of 122 randomized.
Procedures: This will be a prospective, randomized, double-blind, double-dummy, clinical
trial comparing OVB to fluticasone MDI for treatment of EoE. This overall study design will
generate data for all three Aims
Phase:
Phase 4
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)